233 related articles for article (PubMed ID: 23272171)
41. MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway.
Huang G; Lou T; Pan J; Ye Z; Yin Z; Li L; Cheng W; Cao Z
Aging (Albany NY); 2019 Apr; 11(7):2138-2150. PubMed ID: 30981205
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?
Naumann U; Durka S; Weller M
Oncogene; 1998 Sep; 17(12):1567-75. PubMed ID: 9794234
[TBL] [Abstract][Full Text] [Related]
43. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
Peng S; Sen B; Mazumdar T; Byers LA; Diao L; Wang J; Tong P; Giri U; Heymach JV; Kadara HN; Johnson FM
Oncotarget; 2016 Jan; 7(1):565-79. PubMed ID: 26623721
[TBL] [Abstract][Full Text] [Related]
44. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
45. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
Huang RS; Zheng YL; Zhao J; Chun X
Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
[TBL] [Abstract][Full Text] [Related]
46. The canonical NF-κB pathway differentially protects normal and human tumor cells from ROS-induced DNA damage.
Sfikas A; Batsi C; Tselikou E; Vartholomatos G; Monokrousos N; Pappas P; Christoforidis S; Tzavaras T; Kanavaros P; Gorgoulis VG; Marcu KB; Kolettas E
Cell Signal; 2012 Nov; 24(11):2007-23. PubMed ID: 22750558
[TBL] [Abstract][Full Text] [Related]
47. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
48. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
49. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
50. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
51. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
52. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
53. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
54. TP53 drives abscopal effect by secretion of senescence-associated molecular signals in non-small cell lung cancer.
Tesei A; Arienti C; Bossi G; Santi S; De Santis I; Bevilacqua A; Zanoni M; Pignatta S; Cortesi M; Zamagni A; Storci G; Bonafè M; Sarnelli A; Romeo A; Cavallo C; Bartolazzi A; Rossi S; Soriani A; Strigari L
J Exp Clin Cancer Res; 2021 Mar; 40(1):89. PubMed ID: 33673859
[TBL] [Abstract][Full Text] [Related]
55. Insight into the role of PIKK family members and NF-кB in DNAdamage-induced senescence and senescence-associated secretory phenotype of colon cancer cells.
Strzeszewska A; Alster O; Mosieniak G; Ciolko A; Sikora E
Cell Death Dis; 2018 Jan; 9(2):44. PubMed ID: 29352261
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1.
Deng WG; Wu G; Ueda K; Xu K; Roth JA; Ji L
Cancer Gene Ther; 2008 Jan; 15(1):29-39. PubMed ID: 17828283
[TBL] [Abstract][Full Text] [Related]
57. Roles of ERα and ERβ in estrogen-induced DDP chemoresistance in non-small cell lung cancer.
Yu N; Dou L; Li Y; Deng L; Wei X; Guo Y
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706665
[TBL] [Abstract][Full Text] [Related]
58. Apigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner.
Chen M; Wang X; Zha D; Cai F; Zhang W; He Y; Huang Q; Zhuang H; Hua ZC
Sci Rep; 2016 Oct; 6():35468. PubMed ID: 27752089
[TBL] [Abstract][Full Text] [Related]
59. GRP78/BiP determines senescence evasion cell fate after cisplatin-based chemotherapy.
Ei ZZ; Choochuay K; Tubsuwan A; Pinkaew D; Suksomtip M; Vinayanuwattikun C; Chanvorachote P; Chunhacha P
Sci Rep; 2021 Nov; 11(1):22448. PubMed ID: 34789798
[TBL] [Abstract][Full Text] [Related]
60. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]